GT Biopharma Statistics
Total Valuation
GT Biopharma has a market cap or net worth of $13.16 million. The enterprise value is $6.35 million.
Important Dates
The last earnings date was Monday, March 2, 2026, before market open.
| Earnings Date | Mar 2, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
GT Biopharma has 31.55 million shares outstanding. The number of shares has increased by 190.57% in one year.
| Current Share Class | 31.55M |
| Shares Outstanding | 31.55M |
| Shares Change (YoY) | +190.57% |
| Shares Change (QoQ) | +229.33% |
| Owned by Insiders (%) | 1.24% |
| Owned by Institutions (%) | 3.72% |
| Float | 30.72M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 1.84 |
| P/TBV Ratio | 2.27 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 3.50
| Current Ratio | 3.50 |
| Quick Ratio | 2.94 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -97.81 |
Financial Efficiency
Return on equity (ROE) is -1,377.41% and return on invested capital (ROIC) is -377.16%.
| Return on Equity (ROE) | -1,377.41% |
| Return on Assets (ROA) | -125.85% |
| Return on Invested Capital (ROIC) | -377.16% |
| Return on Capital Employed (ROCE) | -214.65% |
| Weighted Average Cost of Capital (WACC) | 10.80% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$34.45M |
| Employee Count | 1 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -82.91% in the last 52 weeks. The beta is 1.19, so GT Biopharma's price volatility has been higher than the market average.
| Beta (5Y) | 1.19 |
| 52-Week Price Change | -82.91% |
| 50-Day Moving Average | 0.61 |
| 200-Day Moving Average | 1.24 |
| Relative Strength Index (RSI) | 34.26 |
| Average Volume (20 Days) | 859,919 |
Short Selling Information
The latest short interest is 2.63 million, so 8.33% of the outstanding shares have been sold short.
| Short Interest | 2.63M |
| Short Previous Month | 2.69M |
| Short % of Shares Out | 8.33% |
| Short % of Float | 8.56% |
| Short Ratio (days to cover) | 1.57 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -12.42M |
| Pretax Income | -28.35M |
| Net Income | -34.45M |
| EBITDA | n/a |
| EBIT | -12.42M |
| Earnings Per Share (EPS) | -$6.25 |
Full Income StatementBalance Sheet
The company has $6.81 million in cash and n/a in debt, with a net cash position of $6.81 million or $0.22 per share.
| Cash & Cash Equivalents | 6.81M |
| Total Debt | n/a |
| Net Cash | 6.81M |
| Net Cash Per Share | $0.22 |
| Equity (Book Value) | 5.79M |
| Book Value Per Share | 0.23 |
| Working Capital | 5.79M |
Full Balance SheetCash Flow
| Operating Cash Flow | -12.91M |
| Capital Expenditures | n/a |
| Free Cash Flow | -12.91M |
| FCF Per Share | -$0.41 |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
